Literature DB >> 3086377

Imipenem susceptibility testing with a commercially prepared dry-format microdilution tray.

J L Staneck.   

Abstract

MICs of imipenem, concurrently generated in commercially prepared microdilution trays containing predried antibiotic dilutions (Sensititre), and in a standard agar dilution assay (as recommended by the National Committee for Clinical Laboratory Standards, Villanova, Pa.), were within +/- 1 twofold dilution for 94% of 226 bacterial isolates. Imipenem biological activity remained stable over 5 months of tray storage at room temperature against Pseudomonas aeruginosa ATCC 27853. Activity of imipenem was shown by microdilution testing with 890 clinical isolates to be high, with only 4% of isolates having MICs of greater than or equal to 16 micrograms/ml (in vitro resistance).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086377      PMCID: PMC268808          DOI: 10.1128/jcm.23.6.1134-1135.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia.

Authors:  J Gutiérrez-Núñez; P T Harrington; C H Ramirez-Ronda
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

2.  Stability of N-formimidoylthienamycin in aqueous solution.

Authors:  G B Smith; E F Schoenewaldt
Journal:  J Pharm Sci       Date:  1981-03       Impact factor: 3.534

3.  Automated reading of MIC microdilution trays containing fluorogenic enzyme substrates with the Sensititre Autoreader.

Authors:  J L Staneck; S D Allen; E E Harris; R C Tilton
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

4.  Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics.

Authors:  T Kesado; K Watanabe; Y Asahi; M Isono; K Ueno
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

5.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

6.  A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.

Authors:  W Cullmann; W Opferkuch; M Stieglitz; U Werkmeister
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

7.  Bioactivity of imipenem as a function of medium, time, and temperature.

Authors:  E J Baron; J A Hindler
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

8.  Effects of storage temperature and pH on the stability of eleven beta-lactam antibiotics in MIC trays.

Authors:  D J Nickolai; C J Lammel; B A Byford; J H Morris; E B Kaplan; W K Hadley; G F Brooks
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

9.  Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates.

Authors:  D L Cohn; L G Reimer; L B Reller
Journal:  J Antimicrob Chemother       Date:  1982-03       Impact factor: 5.790

  9 in total
  5 in total

1.  Validation of the automated reading and incubation system with Sensititre plates for antimicrobial susceptibility testing.

Authors:  Kimberle C Chapin; Michael C Musgnug
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  False resistance to imipenem with a microdilution susceptibility testing system.

Authors:  E J O'Rourke; K G Lambert; K C Parsonnet; A B Macone; D A Goldmann
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

3.  Discrepancies in susceptibility test results for imipenem employing different in vitro test methods and DIN 58,940 breakpoints.

Authors:  H Grimm; C Hauss; A C Rodloff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

Review 4.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

5.  Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels.

Authors:  R L White; M B Kays; L V Friedrich; E W Brown; J R Koonce
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.